# Hyperpolarised combretastatins: potential bio-marker for vascular targeting of tumours.

S. Reynolds<sup>1</sup>, J. Bluff<sup>1</sup>, G. M. Tozer<sup>1</sup>, and M. Paley<sup>1</sup>
<sup>1</sup>School of Medicine, University of Sheffield, Sheffield, United Kingdom

#### Introduction

Vascular targeting of tumours represents a proven complementary approach to conventional cancer therapy. However, effective clinical evaluation of new agents in this field requires the development of imaging bio-markers that can determine tissue pharmacokinetics (PK), early pharmacodynamic (PD) response and measures of resistant tumour phenotypes in early clinical trials. Vascular targeting agents, such as combretastatin A-4-phosphate (CA-4-P, Figure 1), are potentially useful in the treatment of tumours. Using hyperpolarisation (DNP), we aim to investigate the metabolic fate of CA-4-P in a BD9 rat tumour model.

Figure 1: Combretastatin CA-4-P.

### Method

Combretastatin CA-4-P was hyperpolarised using a HyperSense DNP polariser (Oxford Instruments Magnetic Resonance) operating at 1.40K. For  $^{13}$ C hyperpolarisation 4.5mg (10.2mmol) of CA-4-P was dissolved in 200mL of 1:1 methanol-d4:DMSO-d6 and 15mM Finland radical (OIMR). The sample was polarised for  $\sim$ 6h and dissolved using 4mL of methanol. The  $^{13}$ C spectrum was observed using a 90deg pulse-acquire sequence on a JEOL ECA400 spectrometer. To afford the best conditions for observing hyperpolarised combretastatins in vivo, it is favourable to  $^{13}$ C label them at an appropriate position. A complete atom assignment (using 1D  $^{1}$ H, 1D  $^{13}$ C  $^{1}$ H},  $^{13}$ C HSQC,  $^{13}$ C HMBC spectra) was performed using a 400MHz Bruker Avance III spectrometer, with a sample that consisted of 38mM CA-4-P dissolved in  $D_2$ O.

### Results

The hyperpolarised <sup>13</sup>C NMR spectrum for natural abundance CA-4-P contains 6 hyperpolarised peaks, Figure 2. The measured <sup>13</sup>C T<sub>1</sub> and hyperpolarised signal to noise ratios (SNR) for CA-4-P, are displayed in table 1.




Figure 2: Hyperpolarised <sup>13</sup>C { <sup>1</sup>H, inverse gated} spectrum of CA-4-P.

Atom	δ, ppm	T1, s	SNR
1	133.5	2.5	7.5
3/5	152.7	5.6	27
4	136.6	12.3	18
9	130.1	2.6	7.5
12	149.5	6.9	6.8
13	144.5	8.3	7.2

Table 1: <sup>13</sup>C T<sub>1</sub> relaxation times and hyperpolarised SNR values for CA-4-P

## Discussion

The measured  $T_1$ s show, as expected, that quaternary carbon atoms have the longest relaxation times: the longest being the well protected 4 position carbon atom, located on ring 'A'. The longest observed  $^{13}$ C  $T_1$  value for CA-4-P, 12.3s, may provide a small imaging window in which to observe the metabolism of CA-4-P. However, the 4 position is some distance away from the oxidative changes that occur within the molecule on ring 'B', and thus any chemical modification would produce only a modest to negligible chemical shift change at a  $^{13}$ C labelled site. At present, polarisation of CA-4-P could be used for  $^{13}$ C structural images to locate the presence of CA-4-P within the tumour. Strategies to increase the observed  $^{13}$ C  $T_1$  values could be to deuterate the molecule (which may change the kinetics of CA-4-P metabolism) or find combretastatin analogues (including  $^{13}$ C acetyl tagging the molecule) to provide longer  $T_1$  relaxation sites within the molecule.